Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zodasiran · ADS-004

Oligonucleotide (siRNA) · developed by Arrowhead Pharmaceuticals

Phase 3 Most advanced trial

ARWR Developer

2 Registered trials

What is Zodasiran?

Zodasiran is an siRNA that silences ANGPTL3 to reduce circulating lipoproteins. It is being studied in homozygous familial hypercholesterolemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ADS-004, ARO-ANG3
Drug type: Oligonucleotide (siRNA)
Therapy area: Metabolic
Developer: Arrowhead Pharmaceuticals (ARWR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: Y72TWM6CAA

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07473843	Phase 3	Homozygous Familial Hypercholesterolemia	Recruiting	ARWR
NCT07037771	Phase 3	Homozygous Familial Hypercholesterolemia	Active not recruiting	ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Homozygous Familial Hypercholesterolemia

More from Arrowhead Pharmaceuticals

Plozasiran FDA approved ARC-521 Phase 1 ARC-AAT Phase 2 ARO-033 Phase 1 ARO-ALK7 Phase 1/2 ARO-ANG 3 Phase 2 ARO-APOC3 Phase 2 ARO-ATXN2 Phase 1 ARO-C3 Phase 1/2 ARO-CFB Phase 1 ARO-DIMERPA Phase 1/2 ARO-ENaC Phase 1/2

Follow ARWR, the company behind Zodasiran

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z